Biodexa Pharmaceuticals PLC ('Biodexa' or the 'Company') Notice of General Meeting
Biodexa Pharmaceuticals PLC('Biodexa' or the 'Company')
Notice of General Meeting
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 11 June 2025 at 1.00pm was posted to shareholders today.
The Board of Directors is proposing four resolutions:
Ordinary Resolutions
1. That, subject to and conditional on the passing of Resolution 4, each of the issued ordinary shares of £0.001 each in the capital of the Company be subdivided and redesignated into one ordinary share of £0.00005 each and 19 C deferred shares of £0.00005 each (such C deferred shares having the rights and being subject to the restrictions set out in the articles of association of the Company adopted pursuant to Resolution 4). 2. That the Directors of the Company be generally and unconditionally authorised in accordance with Section 551 of the Companies Act 2006 (the 'Act'), in addition to any existing authorities to allot equity securities to the extent unused, to exercise all powers of the Company to allot shares in the Company or to grant rights to subscribe for or convert any security into shares in the Company up to an aggregate nominal value of £476,954.10, provided that this authority shall expire at the conclusion of the Annual General Meeting of the Company to be held in 2028.
Special Resolutions3. That, subject to and conditional upon the passing of Resolution 2, the Directors of the Company be and hereby generally empowered pursuant to Sections 570 of the Act to allot equity securities (within the meaning of Section 560 of the Act) wholly for cash, in addition to any existing authorities to allot equity securities to the extent unused, pursuant to the authority conferred by Resolution 2 as set out in this Notice, as if Section 561 of the Act did not apply to such allotment, provided that this power shall expire at the conclusion of the Annual General Meeting of the Company to be held in 2028.
4. That, subject to and conditional on the passing of Resolution 1, the draft articles of association tabled at the meeting, initialled by the Chairman, and available on the Company's website, www.biodexapharma.com and labelled the 'New Articles', be approved and adopted as the new articles of association of the Company in substitution for and to the entire exclusion of the Company's existing articles of association.
The purpose of the Resolutions is to lower the par value of the ordinary shares and allow the Company to issue ordinary shares above par value.
Neither the number of ordinary shares outstanding nor the number of American Depositary Shares will change as a result of passing of the Resolutions.
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.
eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.
Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.
Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa's headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
Forward-Looking StatementsCertain statements in this announcement may constitute 'forward-looking statements' within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management's belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not anticipate', or 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved.' Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Tutor Perini Building Corp. Awarded $220 Million Eagle Mountain Casino Phase 2 Expansion
LOS ANGELES--(BUSINESS WIRE)--Tutor Perini Corporation (NYSE: TPC) (the 'Company'), a leading civil, building and specialty construction company, announced today that its subsidiary, Tutor Perini Building Corp., has been awarded a contract by the Tule River Gaming Authority valued at approximately $220 million for the Eagle Mountain Casino Phase 2 Expansion. The project is located in Porterville, California. The scope of work includes construction of a new 193-room tower with a rooftop restaurant, a central warehouse and offices, expansion of an existing restaurant, a new 2,000-seat events center with convention space, breakout meeting rooms, pre-function space, and new hotel amenities, including a new spa, arcade and resort pool. Work is expected to commence in the summer of 2025 with substantial completion anticipated in 2027. The contract value is being incrementally added to the Company's backlog, beginning with the preconstruction phase award that was booked in the second quarter of 2025 and later this year as subsequent construction phases are anticipated to be awarded by the customer. About Tutor Perini Corporation Tutor Perini Corporation is a leading civil, building and specialty construction company offering diversified general contracting and design-build services to private customers and public agencies throughout the world. We have provided construction services since 1894 and have established a strong reputation within our markets by executing large, complex projects on time and within budget while adhering to strict safety and quality control measures. We offer general contracting, pre-construction planning and comprehensive project management services, and have strong expertise in delivering design-bid-build, design-build, construction management, and public-private partnership (P3) projects. We often self-perform multiple project components, including earthwork, excavation, concrete forming and placement, steel erection, electrical, mechanical, plumbing, heating, ventilation and air conditioning (HVAC), and fire protection.
Yahoo
2 hours ago
- Yahoo
Should You Buy Microsoft Stock Now or Wait for a Dip?
Microsoft is trading at all-time highs and nearly 40 times its trailing earnings. Its growth rate has been higher than normal as the business has benefitted from artificial intelligence. 10 stocks we like better than Microsoft › Shares of Microsoft (NASDAQ: MSFT) are up 18% this year (returns as of June 27), and that has pushed the stock to a new all-time high. It's been a traditionally safe stock to own, but it's definitely expensive these days, trading at around 38 times its trailing earnings. The business has many growth opportunities and has been a big player in artificial intelligence (AI), which has investors bullish on its long-term future. But given its high valuation, should you consider waiting for a dip in price before adding the stock to your portfolio? Entering trading this week, Microsoft's valuation was at record levels, with a market cap of $3.7 trillion. It's one of the most highly valued stocks on the market today, trailing only Nvidia. But market cap alone doesn't tell investors if a stock is overpriced or not. Looking at a stock's price-to-earnings (P/E) multiple can be an effective way to gauge its relative value. You can compare it to other stocks or even look at its historical average. And based on its 10-year average P/E, Microsoft does indeed look like an expensive stock right now. The stock doesn't look wildly expensive based on the above figure, but investors do appear to be paying a higher premium for the business these days. A higher P/E multiple can be justifiable if a business is performing particularly well and growing at a higher rate than normal, or if it has a big growth catalyst -- such as AI. In recent years, Microsoft has expanded through its acquisition of video gaming company Activision-Blizzard and its heavy investments in AI. Currently, its AI business is generating revenue at an annual run rate of $13 billion, which is a modest amount for a tech company whose sales over the trailing 12 months have totaled $270 billion. There's still potentially much more growth ahead if demand for AI-powered PCs picks up. Unfortunately, with consumers scaling back on spending amid turbulent economic conditions, it may take some time before that may have any sizable impact on its operations. Microsoft is a good long-term investment, but I wouldn't buy it today. At such a high valuation, I don't think it's generating nearly enough growth to justify such a high premium, especially when there are many cheaper AI stocks to choose from; there's not nearly a compelling enough reason to invest in Microsoft right now. I'd put the stock on a watch list, but I wouldn't buy it at its current valuation. There's not much margin of safety and if there's a slowdown in tech spending, especially if companies worry about an economic downturn, then there could be considerable room for the stock to fall. Before you buy stock in Microsoft, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Microsoft wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $722,181!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $968,402!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Microsoft and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Should You Buy Microsoft Stock Now or Wait for a Dip? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Horizon Bancorp, Inc. Announces Conference Call to Review Second Quarter Results on July 24
MICHIGAN CITY, Ind., July 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ GS: HBNC) – Horizon Bancorp, Inc. ('Horizon' or the 'Company') will host a conference call at 7:30 a.m. CT on Thursday, July 24, 2025 to review its second quarter 2025 financial results. The Company's second quarter 2025 news release will be published after markets close on Wednesday, July 23, 2025. It will be available at Participants may access the live conference call on July 24, 2025 at 7:30 a.m. CT (8:30 a.m. ET) by dialing 833-974-2379 from the United States, 866-450-4696 from Canada, or 412-317-5772 from international locations and requesting the 'Horizon Bancorp Call.' Please dial in approximately 10 minutes prior to the call. A telephone replay of the call will be available approximately one hour after the end of the conference call through August 1, 2025. The telephone replay may be accessed by dialing 877-344-7529 from the United States, 855-669-9658 from Canada, or 412-317-0088 from other international locations and entering the access code 5878909. About Horizon Bancorp, Inc. Horizon Bancorp, Inc. (NASDAQ GS: HBNC) is the $7.6 billion-asset commercial bank holding company for Horizon Bank, which serves customers across diverse and economically attractive Midwestern markets through convenient digital and virtual tools, as well as its Indiana and Michigan branches. Horizon's retail offerings include prime residential and other secured consumer lending to in-market customers, as well as a range of personal banking and wealth management solutions. Horizon also provides a comprehensive array of in-market business banking and treasury management services, as well as equipment financing solutions for customers regionally and nationally, with commercial lending representing over half of total loans. More information on Horizon, headquartered in Northwest Indiana's Michigan City, is available at and Contact: Mark E. Secor Chief Administration Officer Phone: 219-873-2611 Date: July 1, 2025Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
